AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02784938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Empowerment Photovoice (VEP)
Description: The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: SCT510 Injection
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab Injection
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel Injection
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel Injection
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin injection
Study NCT03792074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin injection
Study NCT03832257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHO CT Intervention
Description: weekly video conference between hospitalist and skilled nursing facilities
Study NCT03832257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Matched Non-Participating Facilities
Description: Matched Non-Participating Facilities
Study NCT00149500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Patients received monthly calls to assist in behavioral change relative to asthma care
Study NCT02246920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: 50 mcg/actuation Nasal Spray
Study NCT02246920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flonase®
Description: 50 mcg/actuation Nasal Spray
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating, Active Play, Self-Regulation, Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT00372437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 as an oral dose three times per week.
Study NCT00372437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m\<2> intravenously days 1, 8, 15 of a 28 day cycle.
Study NCT02483741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: This material is going to be placed into the sockets of the extracted third molars in the experimental group
Study NCT02021409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
Study NCT02021409 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Study NCT00094757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin 100 mg
Description: sitagliptin 100 mg oral tablet once daily for 54 weeks
Study NCT00094757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin 200 mg
Description: sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
Study NCT00094757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo oral tablet once daily during Phase A (Weeks 0-18)
Study NCT00094757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
Study NCT03440359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Vaginal Gel 8%
Description: progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
Study NCT03440359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole Oral Tablet
Description: letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
Study NCT03440359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole Oral Tablet
Description: letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
Study NCT03440359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic ultrasound
Description: pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is >17 mm in diameter
Study NCT03440359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pelvic ultrasound
Description: pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is >17 mm in diameter
Study NCT03440359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
Description: ovidrel 250 mcg given when leading follicle size is > 17 mm in diameter
Study NCT03440359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
Description: ovidrel 250 mcg given when leading follicle size is > 17 mm in diameter
Study NCT03440359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intrauterine insemination or timed intercourse
Description: Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
Study NCT03440359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination or timed intercourse
Description: Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
Study NCT00518479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
Study NCT00518479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg OD; Moxonidine 400mcg OD
Study NCT03739528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin + dexamethasone followed by dexamethasone
Description: Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
Study NCT03739528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin + Dexamethasone
Description: Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Study NCT02710409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0
Study NCT02710409 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine A
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0
Study NCT02710409 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine B
Description: 0.5 ml/vial, one dose, intramuscular injection on day 0
Study NCT00087373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-TRICOM vaccine
Description: Given intratumorally
Study NCT00087373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01906125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib capsule: phase 1 and 2 studies
Description: 125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
Study NCT02246920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Nasal Spray
Study NCT03110302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure
Description: PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
Study NCT03110302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
Study NCT01906125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib capsule: phase 3 studies
Description: 125 mg dose of palbociclib. Formulation used in phase 3 studies
Study NCT01906125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib capsule: ICH
Description: 125 mg dose of palbociclib. Intended final market formulation
Study NCT00788645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD self care advice
Description: Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
Study NCT02910037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mNGS for pathogen detection
Description: This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
Study NCT01185821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Study NCT00788645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor weather forecast warning
Description: Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
Study NCT03429127 — intervention group
Intervention type: OTHER
Intervention: Normal saline
Description: Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
Study NCT03802682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
Study NCT03429127 — intervention group
Intervention type: OTHER
Intervention: Balanced fluid
Description: Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
Study NCT04703569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dressing with monolayer high compression elastic bandage
Description: The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
Study NCT04703569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing with Unna boot
Description: The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating, Active Play, Self-Regulation
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating, Active Play, Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating + Active Play
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating, Self-Regulation, Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating + Self-Regulation
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating + Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Only
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play, Self-Regulation, Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT00356642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842470X
Description: GW842470X will be available as a yellow smooth water-in-oil cream.
Study NCT00356642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
Study NCT04282005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic/Bariatric surgery
Description: Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
Study NCT04282005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and Diet
Description: Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
Study NCT02663739 — intervention group
Intervention type: DEVICE
Intervention: Zenith® TXD
Description: Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
Study NCT02346188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: Tablet formulated from 30 mg ferrous fumarate.
Study NCT02346188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc oxide
Description: Tablet formulated from 30 mg zinc oxide
Study NCT02346188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01160601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel / Carboplatin
Description: Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
Study NCT01160601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel / Carboplatin
Description: Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
Study NCT01160601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
Study NCT01109940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457A
Study NCT03653390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EnhanceWellness for Disability (EW-D)
Description: Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
Study NCT03653390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
Study NCT04844255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dietary salt
Description: 2 grams of dietary salt
Study NCT01575795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
Study NCT01575795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose 180mg loading dose
Study NCT03342950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Solution
Description: Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)